2018
Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study
Horn L, Gettinger SN, Gordon MS, Herbst RS, Gandhi L, Felip E, Sequist LV, Spigel DR, Antonia SJ, Balmanoukian A, Cassier PA, Liu B, Kowanetz M, O'Hear C, Fassò M, Grossman W, Sandler A, Soria JC. Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. European Journal Of Cancer 2018, 101: 201-209. PMID: 30077125, DOI: 10.1016/j.ejca.2018.06.031.Peer-Reviewed Original ResearchConceptsTreatment-related adverse eventsBaseline PD-L1 expressionObjective response ratePD-L1 expressionPD-L1Immune cellsGrade treatment-related adverse eventsSurvival rateCell lung cancer cohortLong-term clinical benefitTumor-infiltrating immune cellsTumor cellsPhase IPrevious systemic therapySingle-agent atezolizumabCell lung cancerExploratory subgroup analysisLung cancer cohortAtezolizumab monotherapyAdverse eventsDurable responsesMedian durationSystemic therapyAnticancer immunityPD-1
2007
Randomized phase II study of vandetanib (VAN) alone or in combination with carboplatin and paclitaxel (CP) as first-line treatment for advanced non-small cell lung cancer (NSCLC)
Heymach J, Paz-Ares L, De Braud F, Sebastian M, Stewart D, Eberhardt W, Herbst R, Krebs A, Langmuir P, Johnson B. Randomized phase II study of vandetanib (VAN) alone or in combination with carboplatin and paclitaxel (CP) as first-line treatment for advanced non-small cell lung cancer (NSCLC). Journal Of Clinical Oncology 2007, 25: 7544-7544. DOI: 10.1200/jco.2007.25.18_suppl.7544.Peer-Reviewed Original ResearchNon-small cell lung cancerProgression-free survivalAdvanced non-small cell lung cancerRandomized phase II trialPhase II trialOverall survivalII trialMedian progression-free survivalRandomized phase II studyCTC grade 2Daily oral agentObjective response ratePlasma angiogenic factorsPhase II studyFirst-line treatmentCell lung cancerExploratory subgroup analysisFemale ptsCNS metastasesEligible patientsMonotherapy armSecondary endpointsSquamous histologyII studyOral agents
2006
A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results
Heymach J, Johnson B, Prager D, Csada E, Roubec J, Pesek M, Spasova I, Hou J, Kennedy S, Herbst R. A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results. Journal Of Clinical Oncology 2006, 24: 7016-7016. DOI: 10.1200/jco.2006.24.18_suppl.7016.Peer-Reviewed Original ResearchProgression-free survivalAdverse eventsDose interruptions/reductionsMedian progression-free survivalAsymptomatic QTc prolongationCommon adverse eventsDaily oral agentPhase II trialDouble-blind studyOverall survival dataPhase III evaluationPlatinum-based chemotherapyCell lung cancerExploratory subgroup analysisLung cancer histologyRET receptor tyrosine kinaseCNS metastasesPFS prolongationMetastatic NSCLCII trialOral agentsOverall survivalQTc prolongationFatal episodesSubgroup analysis